KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Net Cash Flow (2017 - 2025)

Bionano Genomics' Net Cash Flow history spans 7 years, with the latest figure at -$463000.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 96.34% year-over-year to -$463000.0; the TTM value through Sep 2025 reached -$6.1 million, up 76.43%, while the annual FY2024 figure was -$8.7 million, 168.37% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$463000.0 at Bionano Genomics, down from -$52000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $323.6 million in Q1 2021 and bottomed at -$191.8 million in Q3 2021.
  • The 5-year median for Net Cash Flow is -$523000.0 (2022), against an average of -$1.9 million.
  • The largest YoY upside for Net Cash Flow was 3630.14% in 2021 against a maximum downside of 11565.51% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$116.2 million in 2021, then soared by 80.41% to -$22.8 million in 2022, then increased by 26.77% to -$16.7 million in 2023, then skyrocketed by 102.43% to $405000.0 in 2024, then crashed by 214.32% to -$463000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Net Cash Flow are -$463000.0 (Q3 2025), -$52000.0 (Q2 2025), and -$6.0 million (Q1 2025).